Samsung Biologics to acquire U.S. drug manufacturing facility from GSK
Samsung Biologics will acquire a drug manufacturing facility in the United States from GlaxoSmithKline for $280 million, marking its first production foothold in the country as it seeks to strengthen supply chain resilience.
